Diagnostic value of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in Crohn’s disease

Chen, Gaoli; Xiong, Daqian; Jiang, Zhongchao; Zhang, Chaoming; Hu, Quan

doi:10.11569/wcjd.v26.i2.93

Cited by 2 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twenty-four studies compared NLR values in patients with CD [ 35 , 36 , 50 , 51 , 52 , 53 , 54 , 55 , 56 ], UC [ 35 , 36 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 ], or IBD to NLR values in non-IBD controls [ 69 , 70 , 71 ].…”

Section: Resultsmentioning

confidence: 99%

“…CD: Ahmad et al [ 36 ], Chen et al (2018) [ 52 ], Feng et al [ 54 ], Gao et al (2015) [ 55 ], and Zhou et al [ 50 ] reported significantly higher NLR values in patients with CD than in healthy controls ( p < 0.05, =0.034, <0.01, <0.001, and <0.001, respectively). Zhang et al (2017) [ 56 ] and Acarturk et al [ 35 ] reported significant differences in NLR between patients with active CD compared to healthy controls ( p < 0.005 and <0.001, respectively), but not between patients with inactive disease compared to controls (both p > 0.05).…”

Section: Resultsmentioning

confidence: 99%

“…CD: NLR was assessed to distinguish patients with CD from healthy controls by Chen et al (2018) [ 52 ] using a cutpoint at 2.85 (69.2% sensitivity, 76.2% specificity); by Feng et al [ 54 ] using a cutpoint at 2.72 (68.3% sensitivity, 75.9% specificity); and by Gao et al (2015) [ 55 ] using a cutpoint at 2.13 (82.7% sensitivity, 76.9% specificity, 80.9% overall accuracy). Uniquely, Bou Jaoude et al [ 51 ] attempted to distinguish CD from IBS using a cutpoint of 1.98, though it did not reach statistical significance ( p = 0.177).…”

Section: Resultsmentioning

confidence: 99%

“…Our review identified numerous studies that reported higher NLR values in patients with IBD versus healthy controls (e.g., Gao et al (2015) [ 55 ] and Zhang et al (2021) [ 57 ]). ROC curve analyses have indicated that NLR cutpoints ranging from 2.13 to 2.85 could distinguish patients with CD from healthy controls [ 52 , 54 , 92 ], and cutpoints ranging from 2.26 to 4.70 could distinguish patients with UC from healthy controls [ 63 , 66 ].…”

Section: Discussionmentioning

confidence: 99%

“…Twenty-four studies compared NLR values in patients with CD [35,36,[50][51][52][53][54][55][56], UC [35,36,[56][57][58][59][60][61][62][63][64][65][66][67][68], or IBD to NLR values in non-IBD controls [69][70][71]. [55], and Zhou et al [50] reported significantly higher NLR values in patients with CD than in healthy controls (p < 0.05, =0.034, <0.01, <0.001, and <0.001, respectively).…”

Section: Nlr Differences In Ibd Vs Non-ibdmentioning

confidence: 99%

See 4 more Smart Citations

Inflammatory Bowel Disease and Neutrophil–Lymphocyte Ratio: A Systematic Scoping Review

Langley

Guedry

Goldenberg

et al. 2021

JCM

View full text Add to dashboard Cite

Neutrophil–lymphocyte ratio (NLR) is a biomarker of the systemic inflammatory response. The objective of this systematic scoping review was to examine the literature on NLR and inflammatory bowel disease (IBD). PubMed, Embase, Cochrane CENTRAL, CINAHL, ClinicalTrials.gov, Cochrane Specialized Register, DOAJ, PDQT, Biosis Citation Index, Scopus, and Web of Science were systematically searched. A total of 2621 citations yielding 62 primary studies were synthesized under four categories: distinguishing patients with IBD from controls, disease activity differentiation, clinical outcome prediction, and association of NLR with other IBD biomarkers. Thirty-eight studies employed receiver operating characteristic (ROC) curve analysis to generate optimal NLR cutpoints for applications including disease activity differentiation and prediction of response to treatment. Among the most promising findings, NLR may have utility for clinical and endoscopic disease activity differentiation and prediction of loss of response to infliximab (IFX). Overall findings suggest NLR may be a promising IBD biomarker. Assessment of NLR is non-invasive, low cost, and widely accessible given NLR is easily calculated from blood count data routinely and serially monitored in patients with IBD. Further research is justified to elucidate how evaluation of NLR in research and clinical practice would directly impact the quality and cost of care for patients living with IBD.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Nlr Differences In Ibd Vs Non-ibdmentioning

confidence: 99%

See 3 more Smart Citations

Inflammatory Bowel Disease and Neutrophil–Lymphocyte Ratio: A Systematic Scoping Review

Langley

Guedry

Goldenberg

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

Abnormal platelet parameters in inflammatory bowel disease: a systematic review and meta-analysis

Xu,

Song,

et al. 2024

BMC Gastroenterol

View full text Add to dashboard Cite

Background Platelet dysfunction plays a critical role in the pathogenesis of inflammatory bowel disease (IBD). Despite clinical observations indicating abnormalities in platelet parameters among IBD patients, inconsistencies persist, and these parameters lack standardization for diagnosis or clinical assessment. Methods A comprehensive search was conducted in the PubMed, Embase, Web of Science, and Cochrane Library databases for relevant articles published up to December 16th, 2023. A random-effects model was employed to pool the weighted mean difference (WMD) and 95% confidence interval (95% CI) of platelet count (PLT), mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT) between IBD patients and healthy controls, and subgroup analyses were performed. Results The meta-analysis included 79 articles with 8,350 IBD patients and 13,181 healthy individuals. The results revealed significantly increased PLT and PCT levels (WMD: 69.910, 95% CI: 62.177, 77.643 109/L; WMD: 0.046%, 95% CI: 0.031%, 0.061%), and decreased MPV levels (WMD: -0.912, 95% CI: -1.086, -0.739 fL) in IBD patients compared to healthy individuals. No significant difference was found in PDW between the IBD and control groups (WMD: -0.207%, 95% CI: -0.655%, 0.241%). Subgroup analysis by disease type and disease activity showed no change in the differences for PLT, PCT, and MPV in the ulcerative colitis and Crohn’s disease groups, as well as the active and inactive groups. Notably, the active group exhibited significantly lower PDW levels than the control group (WMD: -1.138%, 95% CI: -1.535%, -0.741%). Conclusions Compared with healthy individuals, IBD patients display significantly higher PLT and PCT and significantly lower MPV. Monitoring the clinical manifestations of platelet abnormalities serves as a valuable means to obtain diagnostic and prognostic information. Conversely, proactive measures should be taken to prevent the consequences of platelet abnormalities in individuals with IBD. Systematic review registration PROSPERO CRD42023493848.

show abstract

Diagnostic value of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in Crohn’s disease

Cited by 2 publications

References 0 publications

Inflammatory Bowel Disease and Neutrophil–Lymphocyte Ratio: A Systematic Scoping Review

Inflammatory Bowel Disease and Neutrophil–Lymphocyte Ratio: A Systematic Scoping Review

Abnormal platelet parameters in inflammatory bowel disease: a systematic review and meta-analysis

Contact Info

Product

Resources

About